by Tara Fernandez | Feb 20, 2020
Immunotherapies have been heralded as a revolutionary paradigm shift in how cancer is treated, thanks to the exceptional cancer-killing properties of checkpoint inhibitors and chimeric antigen receptor (CAR) T cells. Today, approved therapies Yescarta™ and Kymriah™,...
by Sara M. Nolte | Feb 14, 2020
We’ve spent a lot of time swooning over CAR T-cells and CRISPR here at Signals, but recently a potential up-and-coming leading lady in the gene and cancer therapy fields has caught our eye. Our interest was piqued by a recent press release from The Max Delbruck Center...
by Lisa Willemse | Jan 9, 2020
It’s no secret that biology is unpredictable, random and sometimes messy. This is precisely what gives living organisms their singularity and uncanny ability to adapt. But as important as these traits might be in a herd of elephants as they adapt to climate change or...
by Farah Qaiser | Oct 30, 2019
Earlier this month, over 8,900 individuals (including me!) headed to Houston to attend the 2019 American Society of Human Genetics’ (ASHG) Annual Meeting and learn more about cutting-edge research, science literacy and policy issues in the fields of genetics and...
by Tara Fernandez | Oct 24, 2019
In a dark corner of the nucleus, a mutation lurks, up to no good. It stealthily swaps a DNA base – an A to a T – gleefully awaiting the catastrophic consequences on the encoded protein. A brave CRISPR molecule enters the nucleus and armed with its...
by Tara Fernandez | Oct 17, 2019
RNA-based vaccines have been heralded as a new molecular weapon in the arsenal against cancer and infections. Five years ago, they were thrust into the spotlight following a $52 million investment by the Bill and Melinda Gates Foundation to CureVac, a...
Comments